An incorrect table was submitted earlier this year as part of the article "Canadian recommendations for the treatment of glioblastoma multiforme" ( Mason WP, Del Maestro R, Eisenstat D, *et al. Curr Oncol* 2007;14(3):110--17). The corrected version follows:

###### 

Effect of methylation status of methylguanine [dna]{.smallcaps} methyltransferase ([mgmt]{.smallcaps}) promoter on progression-free survival ([pfs]{.smallcaps}) and overall survival ([os]{.smallcaps}) in patients receiving radiotherapy plus temozolomide ([tmz]{.smallcaps}) versus radiotherapy ([rt]{.smallcaps}) alone[a](#tfn1-co14_5p164a){ref-type="table-fn"}

  Clinical endpoint                       [tmz]{.smallcaps} + [rt]{.smallcaps} (*n* = 106)   [rt]{.smallcaps} (*n* = 100)
  --------------------------------------- -------------------------------------------------- ------------------------------
  Methylated [mgmt]{.smallcaps} (*n*)     46                                                 46
   6-Month [pfs]{.smallcaps}              68.9                                               47.8
   2-Year [os]{.smallcaps}                46.0                                               22.7
  Unmethylated [mgmt]{.smallcaps} (*n*)   60                                                 54
   6-Month [pfs]{.smallcaps}              40.0                                               35.2
   2-Year [os]{.smallcaps}                13.8                                               \<2

Adapted from Hegi ME, Diserens AC, Gorlia T, *et al.* [mgmt]{.smallcaps} gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997--1003.
